Edan Instruments Inc
Edan Instruments Inc maintains a strong liquidity position, with a current ratio of 4.67 and a debt-to-equity ratio of 0.02, indicating minimal leverage and a conservative capital structure. The company's liquidity is further supported by a free cash flow of 157.5 million CNY, which provides flexibility for reinvestment or shareholder returns. However, the risk assessment notes that net cash is negative after subtracting total debt, suggesting potential short-term liquidity constraints. Profitability metrics show that Edan Instruments Inc is performing well relative to industry standards. The company's return on equity (ROE) of 13.94% and return on assets (ROA) of 11.56% are strong indicators of efficient capital use and asset management. Gross profit of 1.16 billion CNY and operating income of 311.6 million CNY reflect solid cost control and pricing power in its core markets. Geographically, the company's revenue is concentrated in its domestic market, with no disclosed international revenue segments. This concentration may expose the company to regulatory and economic risks specific to its home region. The company operates in a single business segment, which simplifies its operations but also limits diversification benefits. Looking ahead, Edan Instruments Inc is projected to maintain a stable growth trajectory. Analysts expect the company to report an EPS of 0.61 CNY, up from the last reported 0.53 CNY, indicating a positive earnings outlook. The company's revenue of 1.999 billion CNY in the latest period suggests a strong foundation for future growth, though the absence of disclosed revenue growth rates makes it difficult to assess acceleration. The risk assessment highlights a medium liquidity risk and a low dilution risk. The company's low dilution risk is supported by the absence of dilutive shares and a stable share count. However, the negative net cash position after debt subtraction introduces some uncertainty regarding short-term liquidity. Recent events, including analyst estimates and financial disclosures, indicate a positive sentiment among investors. The company has received a strong-buy recommendation from one analyst, with no hold, buy, or sell ratings, suggesting a favorable outlook. No recent filings or transcripts have been disclosed that would indicate significant operational or strategic changes.
Business. Edan Instruments Inc designs, develops, and sells advanced medical equipment and technology, primarily focused on diagnostic and monitoring devices for healthcare applications.
Classification. Edan Instruments Inc is classified under the Healthcare Services & Equipment business sector and the Advanced Medical Equipment & Technology industry, with a confidence level of 0.92.
- Edan Instruments Inc maintains a strong liquidity position with a current ratio of 4.67 and a low debt-to-equity ratio of 0.02.
- The company's profitability is robust, with ROE of 13.94% and ROA of 11.56%, indicating efficient capital and asset use.
- Revenue is concentrated in a single geographic and business segment, which may increase exposure to regional and sector-specific risks.
- Analysts project a positive earnings outlook, with an expected EPS of 0.61 CNY, up from the last reported 0.53 CNY.
- The company faces a medium liquidity risk and a low dilution risk, with no dilutive shares outstanding.
- --
- ## RATIONALES
- ```json
- Net cash is negative after subtracting total debt.